| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RSHL1 |
| Uniprot No | Q9H0K4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-717 aa |
| 活性数据 | MGDLPPYPER PAQQPPGRRT SQASQRRHSR DQAQALAADP EERQQIPPDA QRNAPGWSQR GSLSQQENLL MPQVFQAEEA RLGGMEYPSV NTGFPSEFQP QPYSDESRMQ VAELTTSLML QRLQQGQSSL FQQLDPTFQE PPVNPLGQFN LYQTDQFSEG AQHGPYIRDD PALQFLPSEL GFPHYSAQVP EPEPLELAVQ NAKAYLLQTS INCDLSLYEH LVNLLTKILN QRPEDPLSVL ESLNRTTQWE WFHPKLDTLR DDPEMQPTYK MAEKQKALFT RSGGGTEGEQ EMEEEVGETP VPNIMETAFY FEQAGVGLSS DESFRIFLAM KQLVEQQPIH TCRFWGKILG IKRSYLVAEV EFREGEEEAE EEEVEEMTEG GEVMEAHGEE EGEEDEEKAV DIVPKSVWKP PPVIPKEESR SGANKYLYFV CNEPGLPWTR LPHVTPAQIV NARKIKKFFT GYLDTPVVSY PPFPGNEANY LRAQIARISA ATQVSPLGFY QFSEEEGDEE EEGGAGRDSY EENPDFEGIP VLELVDSMAN WVHHTQHILP QGRCTWVNPL QKTEEEEDLG EEEEKADEGP EEVEQEVGPP LLTPLSEDAE IMHLAPWTTR LSCSLCPQYS VAVVRSNLWP GAYAYASGKK FENIYIGWGH KYSPESFNPA LPAPIQQEYP SGPEIMEMSD PTVEEEQALK AAQEQALGAT EEEEEGEEEE EGEETDD |
| 分子量 | 80.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人RSHL1蛋白的模拟参考文献(非真实文献，示例格式仅供参考)：
---
1. **文献名称**: *Expression and Purification of Recombinant Human RSHL1 Protein in Escherichia coli*
**作者**: Zhang L, et al.
**摘要**: 研究描述了通过大肠杆菌表达系统高效表达重组人RSHL1蛋白，并优化纯化流程以获得高纯度蛋白，为后续功能研究提供材料基础。
2. **文献名称**: *Structural Characterization of RSHL1 and Its Role in Cellular Signaling Pathways*
**作者**: Smith J, et al.
**摘要**: 通过X射线晶体学解析了RSHL1的三维结构，发现其与特定激酶相互作用，可能参与调控细胞增殖和凋亡相关信号通路。
3. **文献名称**: *Functional Analysis of RSHL1 in Neurodegenerative Diseases*
**作者**: Tanaka K, et al.
**摘要**: 探讨了RSHL1蛋白在神经元中的表达模式及其对α-突触核蛋白聚集的抑制作用，提示其在神经退行性疾病中的潜在治疗价值。
4. **文献名称**: *RSHL1 as a Biomarker for Cancer Progression: Insights from In Vitro Studies*
**作者**: Chen R, et al.
**摘要**: 基于体外实验发现，RSHL1在多种癌细胞系中显著高表达，并通过调控上皮-间质转化(EMT)促进肿瘤转移，提出其作为癌症诊断标记物的可能性。
---
如需真实文献，建议通过PubMed、Google Scholar或Web of Science等平台，以“Recombinant human RSHL1”或相关关键词检索最新研究。
Recombinant human RSHL1 (RSHL1) protein, also known as Recombinant Human Serum Hyaluronidase 1. is a genetically engineered enzyme derived from the human HYAL1 gene. Hyaluronidases are a class of enzymes that degrade hyaluronic acid (HA), a major component of the extracellular matrix involved in cell migration, tissue remodeling, and inflammation. RSHL1 specifically targets hyaluronic acid, breaking it into smaller oligosaccharides, which may influence processes such as wound healing, angiogenesis, and tumor metastasis.
The recombinant form is produced using expression systems (e.g., mammalian or bacterial cells) to ensure high purity and consistent activity. Its applications span biomedical research and therapeutic development. For instance, RSHL1 is studied for its potential in enhancing drug delivery by increasing tissue permeability, particularly in cancer therapies where HA-rich microenvironments limit drug penetration. Additionally, it has been explored in managing fibrotic disorders and chronic inflammatory conditions linked to HA accumulation.
Recent studies highlight its role in modulating immune responses, as HA degradation products can interact with receptors like CD44 or TLRs, affecting cellular signaling pathways. Despite its promise, challenges remain in optimizing enzymatic stability and minimizing off-target effects in vivo. Ongoing research focuses on engineering variants with improved specificity and evaluating its safety-efficacy profile in preclinical models. RSHL1 exemplifies the intersection of enzymology and therapeutic innovation, offering versatile tools for both mechanistic studies and clinical interventions.
×
